Lindsay M. Kuroki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lindsay M. Kuroki has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Premal H. Thaker
Washington University School of Medicine, St. Louis, MO, USA
125 shared publications - David Michael Mutch
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
122 shared publications - Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri
120 shared publications - Carolyn K. McCourt
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri
120 shared publications - Dineo Khabele
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA
114 shared publications - Mary M. Mullen
Washington University School of Medicine in St. Louis
112 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 210, 63-71
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
- 26 May 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 210, 63-71
Open AccessMolecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
- Open Access
- 6 May 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Addressing Cervical Cancer Screening Disparities: At-Home Self-Collection Among LGBQ+ Populations
Background: Over 20 million people in the U.S. are behind on cervical cancer screenings (CCS). Sexual minority populations are 50% less likely to engage in routine screening, putting them at higher risk for cervical dysplasia and cancer due to undetected precancer and delayed diagnosis. Their barriers to speculum exams include access to care, sexual trauma, and provider bias. At-home HPV self-collection (SC) offers a clinically accurate, preferred alternative screening method. Objective: To assess clinical agreement, usability, and screening experiences and preferences for an FDA-authorized at-home vaginal SC device among participants who identify as lesbian, gay, bisexual, pansexual, queer, or other non-heterosexual identities (LGBQ+). Methods: SELF-CERV was a prospective, multi-site method-comparison study conducted across 16 U.S. sites. Participants completed SC in a simulated at-home setting and underwent clinician collection with a speculum and cervical brush; paired specimens were tested for primary HPV using the Roche cobas. Surveys assessed barriers to screening, prior screening experiences, usability, and preferences. 609 participants were enrolled; 599 had paired samples, including 74 LGBQ+ participants. Results: Compared with heterosexual participants, LGBQ+ participants more frequently delayed or avoided screening, had lower preventive care engagement, and described worse prior speculum-based screening experiences, including higher pain, discomfort, and aversion. Clinical agreement between self- and clinician-collected specimens was comparable, with no unanticipated safety concerns. The SC device was rated as easy to use and acceptable across groups; LGBQ+ participants reported greater comfort and empowerment and a stronger preference for at-home self-collection. Qualitative comments emphasized privacy and reduced distress, including trauma- and dysphoria-related concerns. Conclusion: At-home SC is a clinically valid, usable, and strongly preferred CCS option, particularly among LGBQ+ populations who experience disproportionate barriers to speculum-based CCS. Broader adoption of FDA-authorized at-home SC paired with telehealth will enable future impact assessment to reduce persistent disparities in CCS for LGBQ+ populations.
- 6 May 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessAddressing Cervical Cancer Screening Disparities: At-Home Self-Collection Among LGBQ+ Populations
Background: Over 20 million people in the U.S. are behind on cervical cancer screenings (CCS). Sexual minority populations are 50% less likely to engage in routine screening, putting them at higher risk for cervical dysplasia and cancer due to undetected precancer and delayed diagnosis. Their barriers to speculum exams include access to care, sexual trauma, and provider bias. At-home HPV self-collection (SC) offers a clinically accurate, preferred alternative screening method. Objective: To assess clinical agreement, usability, and screening experiences and preferences for an FDA-authorized at-home vaginal SC device among participants who identify as lesbian, gay, bisexual, pansexual, queer, or other non-heterosexual identities (LGBQ+). Methods: SELF-CERV was a prospective, multi-site method-comparison study conducted across 16 U.S. sites. Participants completed SC in a simulated at-home setting and underwent clinician collection with a speculum and cervical brush; paired specimens were tested for primary HPV using the Roche cobas. Surveys assessed barriers to screening, prior screening experiences, usability, and preferences. 609 participants were enrolled; 599 had paired samples, including 74 LGBQ+ participants. Results: Compared with heterosexual participants, LGBQ+ participants more frequently delayed or avoided screening, had lower preventive care engagement, and described worse prior speculum-based screening experiences, including higher pain, discomfort, and aversion. Clinical agreement between self- and clinician-collected specimens was comparable, with no unanticipated safety concerns. The SC device was rated as easy to use and acceptable across groups; LGBQ+ participants reported greater comfort and empowerment and a stronger preference for at-home self-collection. Qualitative comments emphasized privacy and reduced distress, including trauma- and dysphoria-related concerns. Conclusion: At-home SC is a clinically valid, usable, and strongly preferred CCS option, particularly among LGBQ+ populations who experience disproportionate barriers to speculum-based CCS. Broader adoption of FDA-authorized at-home SC paired with telehealth will enable future impact assessment to reduce persistent disparities in CCS for LGBQ+ populations.
- Open Access
- 5 March 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 64, 102055
Developing patient-centered educational material to improve colposcopy adherence
- 5 March 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 64, 102055
Open AccessDeveloping patient-centered educational material to improve colposcopy adherence
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer